Delårsrapport for første halvår 2023
BRØNDBYERNES IF FODBOLD A/S
Cvr.nr. 83 93 34 10
Brøndby, den 6. september 2023
SELSKABSMEDDELELSE NR. 13/2023
Delårsrapport første halvår 2023 for perioden 1. januar 2023 - 30. juni 2023
Resumé:
Brøndby IF kvalificerede sig for syvende gang i træk (ud af syv mulige) til Mesterskabsspillet og endte sæsonen 2022/2023 på en femteplads, hvilket desværre ikke gav adgang til europæiske kampe i den nye sæson. Resultat før skat for årets seks første måneder er på -62,8 mio. kr. mod 19,7 mio. kr. i samme periode i 2022. Resultatet før skat for første halvår 2023 er i overensstemmelse med ledelsens forventninger.
Brøndby IF’s nettoomsætning udgør i første halvår 2023 94,3 mio. kr. mod 92,1 mio. kr. i første halvår 2022. Forbedringen kan primært henføres til stigende indtægter relateret til kampafviklingsaktiviteter.
Omkostningerne inkl. af- og nedskrivninger udgjorde i første halvår 2023 -133,5 mio. kr. mod -110,9 mio. kr. i samme periode 2022. Stigningen er primært afledt af øgede personaleomkostninger samt generelle prisstigninger fra inflation i selskabets eksterne omkostninger.
Resultat af transferaktiviteter udgør -20,8 mio. kr. i første halvår 2023 mod 36,3 mio. kr. i første halvår 2022. Udviklingen i resultatet for transferaktivitet skyldes lavere indtægter fra spillersalg og øgede afskrivninger på kontraktrettigheder.
Resultat før skat for første halvår 2023 udgør et underskud på -62,8 mio. kr. (første halvår 2022: Overskud 19,7 mio. kr.). Resultatet for første halvår 2023 er primært negativt påvirket af stigning i selskabets personaleomkostninger samt faldet i resultatet af selskabets transferaktivitet sammenholdt med første halvår 2022.
Brøndby IF har per 30. juni 2023 en likvidbeholdning på 79,7 mio. kr. (første halvår 2022: 76,8 mio. kr.).
Med venlig hilsen
Brøndby IF
Ole Palmå
Administrerende direktør
Information
Yderligere information om denne meddelelse kan fås hos administrerende direktør Ole Palmå på telefon 43 63 08 10.
Vedhæftet fil
For at se dette indhold fra www.globenewswire.com, så skal du give din accept på toppen af denne side.For at se dette indhold fra ml-eu.globenewswire.com, så skal du give din accept på toppen af denne side.
Information om GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg pressemeddelelser fra GlobeNewswire by notified
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra GlobeNewswire by notified
Changes in Sampo Group Executive Committee and Board of Directors1.10.2023 11:05:00 CEST | Press release
SAMPO PLC STOCK EXCHANGE RELEASE 1 October 2023 at 12:05 pm Changes in Sampo Group Executive Committee and Board of Directors Following the completion of the partial demerger of Sampo plc, the Sampo Group Executive Committee (GEC) terms of Patrick Lapveteläinen, former Sampo Group CIO, and Petri Niemisvirta, CEO of Mandatum, have ended. Meanwhile, the new Sampo Group CIO Ville Talasmäki has joined the GEC today. Lapveteläinen and Niemisvirta have moved to Mandatum plc, a new company established in connection with the demerger to take up roles as Full-time Chair of the Board and CEO, respectively. Both Patrick Lapveteläinen and Petri Niemisvirta were members of Sampo GEC since 2001. Following the changes, the strength of the GEC has decreased from seven to six members. As previously communicated, the number of the members of the Board of Directors of Sampo has declined from ten to nine as Johanna Lamminen has left the Board as of today. Lamminen, who has been a member of the Sampo Board
Partial demerger of Sampo completed - Mandatum to be listed on Nasdaq Helsinki1.10.2023 11:00:00 CEST | Press release
SAMPO PLC STOCK EXCHANGE RELEASE 1 October 2022 at 12:00 pm NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA OR SINGAPORE OR ANY OTHER JURISDICTION IN WHICH PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Partial demerger of Sampo completed - Mandatum to be listed on Nasdaq Helsinki The completion of Sampo plc’s partial demerger has today been registered with the Finnish Trade Register and Mandatum has consequently been separated from Sampo Group, in accordance with the decision of Sampo’s Annual General Meeting on 17 May 2023. Nasdaq Helsinki has admitted the shares in Mandatum plc, the company incorporated in the demerger, to trading on the official list from 2 October 2023. - By separating Mandatum from Sampo, we have simplified the Group and created two entities that are well placed to create shareholder value. Sampo becomes a pure P&C insurance group, while Mandatum i
Redomiciliation to Bermuda completed30.9.2023 16:28:35 CEST | Press release
The Hague, September 30, 2023 - Aegon’s Extraordinary General Meeting of shareholders (EGM) today approved the cross-border conversion into a Bermuda Limited company. After the completion of the EGM, the change of Aegon’s legal seat to Bermuda has been effectuated, as a result of which the company became a Bermuda entity: Aegon Ltd. As of October 1, 2023, the Bermuda Monetary Authority will be Aegon’s group supervisor. Aegon shares will continue to be listed on Euronext Amsterdam (AGN) and NYSE (AEG). As at market open on October 2, 2023, trading will commence in Aegon Ltd. shares. The identifiers (such as the ISIN) of the Aegon shares will change: the Aegon Ltd. common shares will have the ISIN BMG0112X1056; andthe Aegon Ltd. common shares held in New York registry form will have the ISIN US0076CA1045 and the CUSIP 0076CA 104.1 More information on the redomiciliation, as well as the documentation relating to it, can be found here. Contacts Media relations Investor relations Richard Ma
Vow ASA: Order received to double production capacity at VGM’s Follum factory30.9.2023 12:00:00 CEST | Press release
On September 30th, 2023, Vow ASA announced that it has received an order from Vow Green Metals AS to enhance the production capacity at their biocarbon production plant in Hønefoss, Norway. This order is an extension of the equipment order received in October 2021, resulting in a new total contract value of NOK 332 million. In addition to some modification on the original equipment order, the expansion will involve the addition of a new process line, effectively doubling the factory's capacity. This will enable the production of up to 20,000 tons of biocarbon annually. The increased capacity is made possible by utilizing self-sufficient renewable gas to power the new reactor technology developed and manufactured by Vow's subsidiary, C. H. Evensen Industriovner AS. This ensures that the expanded capacity remains within the site's power supply limits. Henrik Badin, CEO of Vow ASA, expressed enthusiasm for this solution, emphasizing its ability to enhance efficiency, significantly increas
FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®29.9.2023 22:06:00 CEST | Press release
TOFIDENCE (BIIB800) becomes the first tocilizumab biosimilar to gain FDA approval in the United States FDA approval is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE to the reference product ACTEMRA CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved TOFIDENCE (tocilizumab-bavi) intravenous formulation, a biosimilar monoclonal antibody referencing ACTEMRA. The TOFIDENCE intravenous formulation is approved for the treatment of moderately to severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and systemic juvenile idiopathic arthritis. TOFIDENCE is the first tocilizumab biosimilar approved in the United States. Biosimilars are biologic products that have been demonstrated to have equivalent efficacy and comparable safety as the approved reference product, with the advantage that they may offer cost savings and promote